Vaccine strategies: Optimising outcomes  by Hardt, Karin et al.
Vaccine 34 (2016) 6691–6699Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineVaccine strategies: Optimising outcomeshttp://dx.doi.org/10.1016/j.vaccine.2016.10.078
0264-410X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: AMP, Agence de Médecine Préventive; DTP, diphtheria-tetanus-
pertussis; EPI, Expanded Programme on Immunisation; GAVI, Global Alliance for
Vaccines and Immunisation; HBV, hepatitis B virus; HBsAg, hepatitis B surface
antigen; HPV, human papillomavirus; MMR, combined measles-mumps-rubella
vaccine; MVP, Meningitis Vaccine Project; NESI, Network for Education and Support
in Immunisation; NITAG, National Immunisation Technology Advisory Group;
PAHO, Pan American Health Organization; SAVIC, South African Vaccination and
Immunisation Centre; SIA, supplementary immunisation activities; WHO, World
Health Organization.
⇑ Corresponding author at: GSK Vaccines, Avenue Fleming 20, Parc de la Noire
Epine, B-1300 Wavre, Belgium.
E-mail addresses: karin.hardt@gsk.com (K. Hardt), paolo.bonanni@unifi.it
(P. Bonanni), sue.a.king@gsk.com (S. King), joseignaciosantos56@gmail.com
(J.I. Santos), mostafaelhodhod@yahoo.com (M. El-Hodhod), gzimet@iu.edu
(G.D. Zimet), scott.s.preiss@gsk.com (S. Preiss).Karin Hardt a,⇑, Paolo Bonanni b, Susan King a, Jose Ignacio Santos c, Mostafa El-Hodhod d,
Gregory D. Zimet e, Scott Preiss a
aGSK Vaccines, Avenue Fleming 20, Parc de la Noire Epine, B-1300 Wavre, Belgium
bUniversity of Florence, Department of Health Sciences, Viale GB Morgagni 48, Florence, Italy
cUniversidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
dAin Shams University, Faculty of Medicine, Pediatrics Department, Cairo, Egypt
e Indiana University School of Medicine, Indianapolis, IN, USA
a r t i c l e i n f o a b s t r a c tArticle history:
Available online 23 November 2016
Keywords:
Vaccination
Strategy
National immunisation programme
Coverage
Planning
ImplementationSuccessful immunisation programmes generally result from high vaccine effectiveness and adequate
uptake of vaccines. In the development of new vaccination strategies, the structure and strength of the
local healthcare system is a key consideration. In high income countries, existing infrastructures are usu-
ally used, while in less developed countries, the capacity for introducing new vaccines may need to be
strengthened, particularly for vaccines administered beyond early childhood, such as the measles or
human papillomavirus (HPV) vaccine. Reliable immunisation service funding is another important factor
and low income countries often need external supplementary sources of finance. Many regions also
obtain support in generating an evidence base for vaccination via initiatives created by organisations
including World Health Organization (WHO), the Pan American Health Organization (PAHO), the
Agence de Médecine Préventive and the Sabin Vaccine Institute. Strong monitoring and surveillance
mechanisms are also required. An example is the efficient and low-cost approaches for measuring the
impact of the hepatitis B control initiative and evaluating achievement of goals that have been estab-
lished in the WHO Western Pacific region. A review of implementation strategies reveals differing
degrees of success. For example, in the Americas, PAHO advanced a measles-mumps-rubella vaccine
strategy, targeting different population groups in mass, catch-up and follow-up vaccination campaigns.
This has had much success but coverage data from some parts of the region suggest that children are still
not receiving all appropriate vaccines, highlighting problems with local service infrastructures. Stark dif-
ferences in coverage levels are also observed among high income countries, as is the case with HPV vac-
cine implementation in the USA versus the UK and Australia, reflecting differences in delivery settings.
Experience and research have shown which vaccine strategies work well and the factors that encourage
success, which often include strong support from government and healthcare organisations, as well as
tailored, culturally-appropriate local approaches to optimise outcomes.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Successes in the eradication of smallpox offered high hopes for
vaccines and the control of infectious diseases [1]. This experience
contributed to the Expanded Programme on Immunisation (EPI),
which was introduced in 1974 by the World Health Organization
(WHO) [2]. Comprehensive vaccination programmes were devel-
oped and became the cornerstone of good public health interven-
tion [3].
Although progress has been impressive, global vaccination cov-
erage rates show there is room for improvement, with nearly 19
million infants not receiving routine immunisation, such as three
doses of diphtheria-tetanus-pertussis (DTP) vaccine, in 2014 [4].
More than 60% of these children live in 10 countries in Africa
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of vaccine-preventable diseases in high-income regions show that
there is a need to expand or adapt vaccination strategies world-
wide [1,6].
The benefits of successful vaccination strategies are clear, pro-
viding not only direct protective effects but also sometimes indi-
rect effects among unvaccinated individuals (herd protection)
[7,8]. The consequences of under-vaccination include a shift of
infection to different age groups and rebound effects [9].
Strategies to address vaccine hesitancy are discussed in an
accompanying paper [6]. This paper provides an overview of the
vaccine introduction strategies and the key factors underlying their
effectiveness.2. Key principles of vaccination strategies
The main objective of all vaccination strategies is to meet dis-
ease reduction goals by achieving high levels of immunity in the
targeted population via adequate immunisation coverage and vac-
cine effectiveness (Box 1) [10]. The strategy varies according to the
target of a vaccination programme, which may be selected groups
or whole populations (Table 1). Theoretically, targeting subjects
with the highest risk of disease or its complications would be most
effective, since the rate of prevented cases per administered doseTable 1
Main vaccination strategies and disease reduction goals.
Vaccination strategya Example
vaccine
Goals
Routine vaccination (selective immunisation) To eradicat
Single birth cohort DTP,
Rotavirus
Double cohort (e.g., infants and adolescents) HBV
Mass immunisation (entire population in affected area or
priority risk groupsb)
Response to an emerging epidemic Yellow
fever
To rapidly
preventable
Response to a predicted epidemic Influenza To establish
Response to a diseases outbreak Hepatitis A To establish
reported in
Catch-up vaccination MMR To protect
Specific immunisation campaigns/supplemental
immunisation activities
OPV To eradicat
Abbreviations: DTP = diphtheria-tetanus-pertussis, HBV = hepatitis B virus, MMR = meas
a A combination of strategies may be appropriate, most commonly age-based comple
b Priority risk groups: groups at highest risk of disease morbidity or mortality, such a
Box 1
Main elements of vaccination strategies.
Programmatic objectives  Meet disease reduction goals in targeted
population via
– Adequate immunisation coverage
– Adequate vaccine effectiveness
Factors for an effective
vaccination strategy
 Structure and strength of local healthcare
system
– Infrastructure for vaccine distribution
and administration
– Compatibility with existing immunisa-
tion calendar
– Political will
 Immunisation service funding
 Surveillance and monitoring systems for dis-
ease impact and vaccine coverage
Implementation aspects  Strategy and planning
 Human resources
 Supportive framework
 Advocacy and communicationwould be maximised. Unfortunately, vaccine-preventable diseases
are often not exclusively present in risk groups or there is no par-
ticular risk condition for their acquisition (for instance, measles,
rubella, varicella and rotavirus). The other difficulty lies in the abil-
ity to reach all those at risk, since healthcare systems may fail to
ensure patients receive all recommended vaccines, as discussed
in an accompanying paper [11]. Consequently, age-based strategies
complemented by risk group strategies have been found to be most
effective for disease reduction [12].
For most vaccine-preventable diseases, a single cohort approach
is used in which immunisation is started at a given age (for exam-
ple, 2–3 months for DTP) and the targeted population receives all
recommended doses at specific times. Sometimes a double-
cohort approach is useful to speed up the impact of a vaccination
programme, for instance, simultaneous vaccination of infants and
adolescents or young adults [13,14]. Mass vaccination occurs when
a large number of people are immunised within a short period of
time for efficient disease reduction and generation of herd protec-
tion, depending on the mode of disease transmission [15]. It may
be used in response to an emerging or existing epidemic, such as
polio in the 1950s [16] and, more recently, meningococcal, measles
and yellow fever epidemics in sub-Saharan Africa and Latin Amer-
ica [15]. This programme may also be employed to prevent a pre-
dicted epidemic, such as the annual influenza campaign in
industrialised countries [15]. For catch-up vaccination, in addition
to routine immunisation of an age cohort, other population groups
are actively offered vaccination, usually for a limited time.
Various factors are considered when determining the feasibility
of the immunisation strategy in the targeted population. This
includes the demographic composition of the population to immu-
nise, the age at which most disease cases occur and the biological
and social factors underlying infection transmission that deter-
mine the basic reproductive rate (R0) of the infectious agent
[8,9]. Calculation of the disease burden, expressed in terms of inci-
dence and prevalence rates, associated hospitalisations, disability
and mortality, provides valuable information on the particular dis-
ease and its importance or seriousness compared with other health
conditions [10]. Detailed mathematical models can help make
inferences on the total disease burden when such data are incom-
plete, as well as on spread of infection and critical vaccination cov-
erage [17].
Assuming vaccination is feasible, the strategy for its introduc-
tion must take into account the structure and strength of the local
healthcare system, service funding and means of monitoring suc-
cess. Each of these factors is considered below.e, eliminate or contain disease
limit morbidity and mortality due to the documented presence of a vaccine-
disease
population immunity before risk occurs
population immunity and reduce number of cases after several cases are
a certain area/group of people
individuals whose vaccinations have been delayed or missed
e, eliminate or contain disease, where not achieved by routine vaccination
les-mumps-rubella, OPV = oral poliovirus.
mented by risk group strategies.
s young children, pregnant women, older adults, healthcare professionals.
K. Hardt et al. / Vaccine 34 (2016) 6691–6699 66932.1. Structure and strength of the local healthcare system
The structure and strength of local or national healthcare sys-
tems vary widely, with many developing countries lacking the
means to access, evaluate and implement new vaccines [5,10]. In
the assessment of existing immunisation programmes, areas for
improvement are identified as well as the feasibility of the pro-
posed vaccination schedule in terms of number of clinic visits
required and compatibility with vaccine schedules already in the
immunisation calendar. Political issues also play an important role
[10,18]: strong decision making and political will is needed for
immunisation calendar updates, integration of policies into
national health plans and social mobilisation measures. Infrastruc-
tures may need to be strengthened or new systems developed for
vaccines administered to age groups beyond early childhood [19],
such as vaccines against human papillomavirus (HPV) types that
cause of cervical cancer. Around 85% of cervical cancer cases and
deaths occur in less developed countries [20], predominantly
because of a lack of preventive measures [21–23]. Demonstration
projects conducted in India, Peru, Uganda and Vietnam beginning
in 2006 found that high coverage could be achieved using a variety
of delivery strategies, including school- and health centre-based
strategies, as well as those coupling HPV vaccination with other
health interventions [24]. In India, however, problems were
encountered with unconfirmed adverse events and claims that
the project was an experimental clinical trial [25]. The adverse
events were formally investigated and no deaths were determined
to be caused by the HPV vaccine. Despite this, the trial was shut
down by the government. This shows how a local healthcare system
with adequate structure and strength for delivering a successful
vaccination programme may be undermined by politics, suspicion
of the motives of outside organisations and public distrust.
The factors that are important for successful introduction of
HPV immunisation in low-resource settings were summarised by
Kane et al. (see Box 2) [26]. In particular, investment is often
required to improve infrastructure to ensure efficient vaccineBox 2
Important factors in the policy process for human papillomavirus (HPV) vaccine
introduction in low-resource settings [26].
Policy environment  National disease data on the burden of cervi-
cal cancer
 Priorities of women’s health and cervical can-
cer control
 Priorities in adolescent health
 National immunisation programmes: infras-
tructures and policies
HPV vaccine-specific
issues
 Safety and efficacy data
 Economic modelling of cost-effectiveness and
impact
 Demonstration projects in country or region
 Behaviour of other countries regionally and
globally
 Cost and ‘affordability’ of the vaccine to the
country
 Social perception of vaccine
Policy development and
implementation
 National capacity for HPV vaccine
introduction
 Vaccine financing
 International guidelines from WHO, GAVI,
UNICEF and donors at global, regional and
national levels
 Training on cervical cancer for the staff
involved in HPV vaccination
 Information, education and communication
material
 Appropriate implementation and monitoring
GAVI, Global Alliance for Vaccines and Immunisation; UNICEF, United Nations
Children’s Fund; WHO, World Health Organization.delivery and good coverage, and to reduce vaccine wastage [21].
This includes sufficient centralised vaccine storage space, refriger-
ators to store vaccines at health centres, and walk-in coolers for
vaccination at delivery points (schools or elsewhere). Nurses and
doctors need to be trained in HPV vaccination and in assessing
and managing any side effects or complications. For implementa-
tion through schools, a strategy to reach non-attending girls must
be in place. Achieving these goals requires long-term political sup-
port since, as with other vaccines, HPV vaccination is a long-term
prevention strategy, the benefits of which may only become evi-
dent beyond a government’s term of office.
2.2. Service funding
Immunisation services can only realise their potential to
improve health if there is adequate and reliable funding to ensure
continuity and increases in coverage. Insufficient funding is one of
the main barriers to providing access to vaccines in low income
countries, which often need external sources of finance to supple-
ment government budgets. However, high income countries may
also struggle to keep immunisation budgets sustainable, particu-
larly when new vaccines need to be introduced.
Althoughmost national governments are investingmore in their
national immunisation programmes, new vaccines and higher tar-
get coverage rates are driving costs up [27]. It is therefore important
to assess financial sustainability. For example, a cost comparison of
vaccine introductions in Rwanda found that delivery costs of pneu-
mococcal and rotavirus vaccines were similar since both were
delivered using existing healthcare infrastructure while the cost
of delivering HPV vaccine was higher because a new vaccine deliv-
ery system had to be created for a new target population [28].
To avoid a large financing gap, policy makers in many countries
have had to examine the options available to support immunisa-
tion. This includes initiatives by the Pan American Health Organi-
zation (PAHO), Global Alliance for Vaccines and Immunisation
(GAVI), the International Finance Facility for Immunisation and
the Advanced Market Commitment, which together with various
governments, international agencies and charitable foundations
have provided funds to the world’s poorest countries [29,30]. For
example, the PAHO EPI Revolving Fund allows several countries
with the same vaccine needs to apply for vaccine supplies together,
resulting in a decreased vaccine cost, and handles most aspects of
procurement using a common fund to pay producers before being
reimbursed by countries [30,31].
Various countries have developed other public and private
financing solutions [27]. In countries such as Tajikistan, Vietnam
and Haiti, resources for immunisation are raised through tax levies
on luxury goods, alcohol and tobacco. In Costa Rica, proceeds from
the November drawing of the national lottery are earmarked for
the National Immunisation Fund, providing a minor but stable pro-
portion of the immunisation budget. Other innovative sources of
financing include taxes on exported food products, airline tickets,
mobile phone usage, residential tax and vehicle tax discs. Also,
financing from private sources can be an effective option. In Bhu-
tan, the government established the Health Trust Fund, with the
goal of eliminating funding unpredictability and generating suffi-
cient income to meet the cost of critical components of the coun-
try’s health services [32]. Private and public donor contributions
to the fund are matched by the Bhutanese government. This
approach has been an important tool in ensuring the timely avail-
ability of vaccines and essential drugs.
2.3. Monitoring success
Surveillance mechanisms allow for continuous evaluation of the
coverage, safety and effectiveness of the vaccine [33] and can be
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the programme.
The importance of a strong monitoring programme can be illus-
trated by the experience in Germany following the introduction of
routine vaccination with a single dose of monovalent varicella vac-
cine for young children in 2004 [34]. A sentinel surveillance system
used to monitor the epidemiology of varicella disease showed vac-
cination brought a steep downward trend in disease prevalence
over time, with 55% fewer varicella cases in the 2008–2009 season
compared with 2005–2006 [35]. However, during the same period,
a rising number of breakthrough infections was reported and an
investigation of varicella outbreaks in daycare centres in 2008
and 2009 found vaccine effectiveness after one dose was only
62% [36]. Germany’s National Immunisation Technology Advisory
Group (NITAG) responded by examining these monitoring data,
new vaccine immunogenicity data, and epidemiological informa-
tion and experiences from other countries. Particularly relevant
information came from the USA, where a single dose of monova-
lent varicella vaccine had been administered to children aged
12–18 months since 1996. Despite 80–85% effectiveness in pre-
venting varicella [37], disease outbreaks still occurred, leading to
recommendation in 2007 of a second dose of varicella vaccine for
children [38]. In Germany, after considering all available evidence
and the feasibility of changing the immunisation schedule, the
NITAG recommended in 2009 that the varicella vaccine should be
administered twice [39]. Evidence from regions that adopted the
new dosing schedule showed the number of varicella cases
decreased, indicating that the recommended change was effective
[40].3. Supportive framework for implementation of vaccine
strategies
Different groups and organisations provide supportive frame-
works that encourage successful implementation of vaccine strate-
gies. These focus on various elements including generation of the
evidence base for vaccination, effective presentation of evidence
to policy decision makers and activities to strengthen the capacity
of immunisation programmes.
Policy decisions to introduce new vaccines require an evidence
base that reflects national, and sometimes local, conditions [41].
Many countries generate this evidence base with support from
organisations involved with global immunisation activities, such
as PAHO, the USA Centres for Disease Control and Prevention,
PATH, the Sabin Vaccine Institute, the Agence de Médecine Préven-
tive (AMP) and the WHO. For example, in Latin America and the
Caribbean, the ProVac Initiative was introduced by PAHO in 2004
to train ministry of health technical staff on economic evaluations
for introducing rotavirus, pneumococcal and HPV vaccines [42].
These organisations often collaborate with NITAGs, which are com-
posed of expert committees that make recommendations on vacci-
nation programmes to national authorities. The SIVAC (Supporting
Independent Immunisation and Vaccine Advisory Committees) ini-
tiative, which is led by the AMP in collaboration with the WHO and
funded by the Bill & Melinda Gates Foundation [43], assists in the
establishment or strengthening of functional, sustainable indepen-
dent NITAGs in GAVI-eligible and middle income countries.
Another AMP initiative, the Health Policy and Institutional Devel-
opment unit, encourages systematic use of evidence-informed
policy-making processes in immunisation, collaborates with the
WHO on scaling-up initiatives and facilitates the exchange of infor-
mation within the immunisation community [44].
NITAGs have been established to guide immunisation policies in
most industrialised and some developing countries: in 2015, a
NITAG was in place in 124 countries of which 82 met six basicWHO criteria relating to administrative and legislative practices,
areas of expertise, frequency of meetings and meetings preparation
[45]. A highly functioning NITAG is instrumental in enabling its
national government to form evidence-based vaccination strate-
gies and policies [46]. However, approaches towards providing
immunisation advice vary widely among countries and few NITAGs
have published their model for advice and vaccine funding in peer-
reviewed journals [47,48]. Survey data suggest more NITAGs need
to use health economic assessments as part of their vaccine recom-
mendation processes, in low income countries as well as in high
and middle income countries; a survey of 28 European countries
in 2014 showed 20 used health economic assessments, while
mathematical modelling as part of the recommendation process
was conducted in only 18 countries [48]. This is particularly impor-
tant, in addition to the epidemiology of disease, for cost-benefit
considerations relating to choice of dosage regimen (such as the
decision to administer two or three priming doses of pneumococ-
cal conjugate vaccine with or without booster dose [49]) and target
population, such as high-risk groups (as for seasonal influenza vac-
cine in some countries [50]) versus immunisation of the wider
population, or number of age cohorts to be included in catch-up
vaccination programmes. To help address inconsistencies in
approaches, the NITAG Resource Centre has been developed by
the Health Policy and Institutional Development unit of the AMP
[45]. This online resource aims to provide centralised access to
NITAG related tools, NITAG recommendations from around the
world as well as the background documents used to issue them,
such as systematic reviews and technical reports, and information
on upcoming immunisation events.
Many capacity-building organisations also contribute to suc-
cessful immunisation programmes. Examples include the South
African Vaccination and Immunisation Centre (SAVIC), which is
an academic-public alliance between the Sefako Makgatho Health
Sciences University (previously University of Limpopo) and the
University of Antwerp, Belgium [51], Network for Education and
Support in Immunisation (NESI) based at the University of Antwerp
[52], Vaccines for Africa Initiative based at the University of Cape
Town, South Africa [53], the International Vaccine Institute in the
Republic of Korea [54] and the more recently established East
Africa Centre for Vaccines and Immunisation, administered from
Egerton University, Kenya, and Makerere University College of
Health Sciences, Uganda [55]. These organisations provide inter-
country vaccinology courses and experience exchange workshops
on the introduction of new vaccines, targeting NITAG members
and policy-makers, as well as EPI managers and staff. Specific
training (including the development of training materials) for
healthcare workers delivering the new vaccine may be conducted
as well. The activities aim to strengthen immunisation programme
capacity with technical assistance, training, development of tools
and information sharing, and promote evidence-based decision-
making on new vaccine introduction and efficient management
of immunisation programmes. An example is a two-year capacity
building project entitled ‘Improving skills and institutional capac-
ity to strengthen country adolescent immunisation programmes
and health systems in the African Region’ [56]. Using HPV vaccine
as a case study, this project was implemented in 2014 in eastern
and southern Africa by SAVIC, the South African Medical Research
Council and NESI, funded by the Belgian government and with sup-
port from the WHO regional office for Africa. Through various
experience exchange activities, the project has developed immuni-
sation training materials that can be easily adapted to specific
country needs and is helping create a multidisciplinary team of
experts to support and advocate for the introduction of HPV vacci-
nes in the region.
Other organisations assist with the managerial structures and
processes for delivering vaccination services, such as the newly
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[57]. To support the uptake of vaccination and encourage better
public understanding of its importance, civil society groups
(mostly non-state voluntary organisations, such as health-, child-
or patient-focused advocate groups) can play an important role
[58]. As discussed in an accompanying paper [6], healthcare provi-
ders also have an essential role in optimising vaccine uptake [59].
The collaboration of various public health sector partners is neces-
sary to ensure immunisation programmes are supported suffi-
ciently, including partnership with vaccine manufacturers.
Transparent processes are being introduced for developing, manu-
facturing and monitoring the safety and effectiveness of vaccines,
as well as strategies for providing accurate and reliable informa-
tion on vaccines’ benefit-risk profiles [33].
4. Implementation strategies in different parts of the world
Table 2 outlines some of the many vaccine implementation
strategies that have been employed in different regions with vary-Table 2
Examples of implementation strategies that have been assessed in relation to uptake of v
Intervention tested (year) Vaccine Age group Setting/c
National multivaccination campaign;
national polio immunisation day (2012)
IPV-OPV
(sequential
schedule)
<5 years Brazil
Mass campaigns targeting children,
adolescents and adults; follow-up
campaign targeting unvaccinated
children (2003–2009)
Rubella-
containing
Children,
adolescents,
adults
Americas
Routine immunisation (2011–2013) MMR <5 years Mesoame
Mass vaccination campaign, supplemental
immunisation activities (2010)
Measles 614 years South Afr
Vaccine-preventable disease control goal
(2005–2012)
HBV P5 years WHO We
Pacific re
Vaccination during pregnancy (2013) Pertussis Pregnant
women
England
Vaccination of parents in neonatal ICU
(2007)
Pertussis Parents of
neonates
New Yor
Schoolchild immunisation programme
(1962–1994)
Influenza School-age Japan
Mass vaccination campaign (2008–2011) Influenza Primary
healthcare
workers
Spain
Phased mass vaccination campaign for
priority groups (2010)
Pandemic
influenza
Priority
groups
Brazil
School-based programme (2012–2014) HPV Girls 12–
13 years old
England
School-based catch-up programme (2007–
2009)
HPV Girls 12–
17 years
Australia
Vaccination in medical clinic (2014) HPV Girls 13–
17 years
USA
Abbreviations: HBV, hepatitis B virus; HPV, human papillomavirus; ICU, intensive care un
WHO, World Health Organization.ing degrees of success [60–72]. A few of these strategies are dis-
cussed in more detail below, highlighting the challenges faced as
well as reasons for success.
In the Americas, PAHO advanced a rubella elimination strategy
from 2003, which was combined with a measles elimination strat-
egy [61]. This aimed to achieve at least 95% coverage with rubella-
containing vaccine, mainly measles-mumps-rubella (MMR) vac-
cine, for children aged 12 months in all countries (‘keep up’ cam-
paign). Supplementary immunisation activities (SIAs) included
implementation of a one-time mass campaign among adolescents
and adults (‘speed up’ campaign), catch-up campaigns in children
aged 1–14 years and periodic follow-up campaigns among children
younger than 5 years. By 2010, all countries routinely vaccinated
children against rubella, an estimated 450 million people had been
vaccinated against measles and rubella in SIAs and rubella trans-
mission had been interrupted, with the last confirmed endemic
rubella case reported in 2009. Comparison of different strategies
showed this combined vaccination strategy with a universal
approach was more effective than strategies that focused onaccines or other outcomes.
ountry Main findings/outcomes Reference
Rapid uptake of vaccines (from 5% in August to 67% in
December for two IPV doses) despite challenges with local
vaccine supply due to high wastage rates
[60]
High vaccination coverage (93–94% for first MMR dose at
age 12 months; estimated 450 million people vaccinated
during supplementary immunisation activities) led to
elimination of rubella and congenital rubella syndrome
[61]
rica Vaccination coverage 45–80% (at least one dose). Missed
vaccinations possibly due to vaccine shortages, failures to
immunise at all well-child clinic visits, inadequate
knowledge of current immunisation schedules, lack of
immunisation documentation
[62]
ica Heterogeneity in vaccination coverage (of 52 districts, 8
had coverage <80% for first vaccine dose). Reduction in
routine immunisation coverage associated with
supplemental immunisation activities, which might have a
negative impact on functioning of health systems
[69]
stern
gion
Adopting the regional goal led to greater political
commitment and reduced inequalities in HBV vaccination
between and within countries. Major progress in provision
of HBV birth dose
[63]
Vaccination coverage 60–78%. High vaccine effectiveness
among neonates <3 months old: 78% fall in confirmed cases
and 68% fall in related hospital admissions
[64]
k, USA Vaccination coverage 87%; 11% refused vaccination citing
pertussis as an insignificant threat or disbelief in
vaccination. Short length of ICU stay (<3 days) was logistic
barrier
[65]
Schoolchild programme contributed to reduced influenza-
associated mortality rate among younger children and
people aged 65 years or older
[66]
Low vaccination coverage (49–58%): vaccination rates
decreased over time, especially after pandemic season
[67]
Immunisation target (80%) achieved by 86% of groups
overall and surpassed among several groups, including
very young children, healthcare workers, persons with
chronic illness. Conducting the campaign in phases
facilitated vaccine distribution and service delivery despite
limited vaccine stocks
[68]
Vaccination coverage >86% for 3-dose course. Reduction in
prevalence of HPV 16/18 infections consistent with high
vaccine effectiveness and herd protection
[70]
Vaccination coverage 70% for 3-dose course [71]
Vaccination coverage 40% for 3-dose course [72]
it; IPV, inactivated poliovirus; MMR, measles-mumps-rubella; OPV, oral poliovirus;
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fold greater incidence of rubella in men and disease outbreaks [73].
There is however evidence that the most vulnerable groups are
still not receiving the MMR vaccine in parts of the Americas. In a
recent study of MMR immunisation of children younger than
5 years in low income areas of El Salvador, Guatemala, Honduras,
Mexico, Nicaragua and Panama, conducted for the Mesoamerican
Health Initiative [74], vaccine coverage was 45–80% and the data
indicated that families were bringing their children to health facil-
ities but they were not receiving all appropriate vaccines during
visits [62]. This highlighted major problems that need to be
addressed to prevent missed opportunities: a shortage of vaccines,
failures to immunise at all well-child clinic visits, inadequate
knowledge of current immunisation schedules and a lack of docu-
mentation of vaccinations by healthcare professionals.
Another example of a region-wide policy towards disease pre-
vention involves the response in the WHO Western Pacific region
to a disproportionate burden of hepatitis B virus (HBV) infection
[75]. Most HBV-related deaths occur in adults and common routes
of transmission include perinatal, early asymptomatic childhood
infection, sexual contact, blood transfusions and unsafe injection
practices [76]. Universal vaccination of newborns with three doses
of HBV vaccine, the first within 24 h of birth, was identified as the
most feasible and cost-effective vaccination strategy and was
incorporated into the EPI. In 2005, the Western Pacific region
became the first to adopt the goal of reducing the prevalence of
chronic HBV infection, as indicated by seroprevalence of hepatitis
B surface antigen (HBsAg), to less than 2% in children at least
5 years of age by 2012 [63]. A time-bound supranational control
goal was chosen to create a sense of political urgency for strength-
ening routine immunisation services and improving access to vac-
cines. Moreover, rather than relying on surveillance systems, the
WHO encouraged national serologic surveys to be conducted to
measure HBsAg prevalence in children since disease outcomes
after infection are usually delayed by decades [77]. Also, a regional
verification process was established to ensure standard and inde-
pendent mechanisms for assessing achievement of HBV control
targets, which is conducted by a WHO expert panel, takes approx-
imately 3 months and is an efficient and low-cost approach to
measuring impact [77]. Adopting the regional goal led to greater
political commitment and reduced inequalities in HBV vaccination
between and within countries, with major progress in providing
timely birth doses [63].
The impact of discontinuing a specific vaccination strategy is
illustrated by the experience in Japan with influenza vaccination
[66]. In 1962, the Japanese government introduced a programme
based on the theory that influenza epidemics could be reduced
by vaccinating schoolchildren. It was abandoned in 1994 because
of a lack of evidence that it had limited the spread of influenza in
the community. However, comparison of influenza-related mortal-
ity in Japanese people aged 65 years or older during the vaccina-
tion programme with mortality after the programme was
discontinued showed a 36% increase among Japanese seniors, cor-
responding to around 1,000 additional deaths annually [78]. There
was also an increase in influenza-associated deaths among
younger children following discontinuation of the schoolchild vac-
cination programme, with an estimated 783 excess deaths among
children aged 1–4 years from 1990 to 2000 [79]. When the vacci-
nation programme was in effect, Japanese schoolchildren therefore
appear to have served as a barrier against the spread of influenza in
the community.
The response to a pertussis (whooping cough) outbreak pro-
vides an example where different strategies to decrease disease
transmission were evaluated. In England, pertussis-containing vac-
cines had been administered at 2–4 months of age since 1990 withgood coverage but in 2011, a national increase in pertussis cases
was reported, initially in adolescents and adults but extending to
young infants in 2012 [80]. Since infants are at particular high risk
for pertussis-related complications and death [81], their protection
was of high priority. Strategies to optimise control of pertussis in
infants that were considered included vaccination of pregnant
women, adolescents or close contacts (‘cocooning’) [80,82]. There
was little evidence that an adolescent booster had an impact on
infant pertussis. Cocooning can be very costly and resource-
intensive to implement because of the need to vaccinate all indi-
viduals who have close contact with infants younger than
6 months, and acceptance of vaccination by all close contacts can
be challenging [82]. There was however sufficient evidence of pro-
tection by maternal antibodies following vaccination in pregnancy
[80]. Consequently, the UK Department of Health recommended a
temporary maternal pertussis immunisation programme to min-
imise morbidity and prevent further infant deaths. An observa-
tional study of the programme showed high vaccine
effectiveness, with a 78% fall in confirmed cases of pertussis in
infants younger than 3 months and 68% fall in related hospital
admissions [64]. This and other demonstrations of the effective-
ness and safety of maternal vaccination against pertussis has led
the Global Pertussis Initiative to recommend immunisation during
pregnancy as the primary strategy to prevent pertussis in infants
[82]. Moreover, a recent analysis of the temporary programme in
England found that it was highly cost effective in 2012 and, com-
pared with the existing paediatric vaccination programme, had
the major benefit of offering direct protection of the highly vulner-
able infant population [83]. Policymakers therefore decided in
2014 to keep maternal vaccination in place in the UK for at least
another 5 years, with re-evaluation of its cost effectiveness in light
of the future epidemiology of pertussis.
The impact of employing different strategies is demonstrated by
the dramatically different approaches to HPV vaccination across
high income countries, such as the USA versus the UK and Australia
[25]. In the USA, most vaccines, including HPV vaccine, are deliv-
ered to individual patients in medical clinic settings. High vaccina-
tion rates are typically achieved through laws enacted in each state
requiring receipt of certain vaccines for school entry but few states
have school-entry requirements for HPV vaccination. As a result,
HPV vaccination rates in the USA remain relatively low, with
2014 national data indicating that 40% of 13–17 year-old girls
had completed the three-dose series [72]. In contrast, the UK and
Australia have delivered HPV vaccines principally via school-
located programmes, which allow for immunisation of large
groups of youths over a relatively short span of time. In these coun-
tries, the three-dose completion rate for girls ranges from about
70–86%, much higher than rates in the USA [70,71]. Also, evidence
from the hepatitis B school-located vaccination programme in the
USA suggests that the cost of vaccinating via school can be signif-
icantly lower than immunising adolescents via a health mainte-
nance Organization [84].5. Importance of communication strategies
The communication strategy that accompanies an immunisa-
tion programme should encourage sustained support by healthcare
policy makers and demand for the vaccine from healthcare work-
ers and the public. Support from policy makers is encouraged via
a communication and advocacy strategy that ensures the relevant
evidence reaches stakeholders and decision-makers. An example is
the communication strategy developed by the Sabin Vaccine Insti-
tute for the evidence base generated through PAHO’s ProVac Initia-
tive (see Box 3) [41].
Box 3
Guides for communication strategies targeted towards healthcare policy makers, the
public, healthcare workers, community leaders and the media. Based on strategies
developed by the Sabin Vaccine Institute for evidence generated through ProVac
studies [41] and by the World Health Organization and PATH for the Meningitis
Vaccine Project [85].
Target of communication
strategies
Recommended approaches
Healthcare policy makers  Analyse the country’s existing deci-
sion-making process for introducing
new vaccines
 Identify stakeholders and their roles in
the decision process
 Identify relevant evidence that should
be used to properly inform the decision
 Address common questions about cost-
effectiveness and its role in the deci-
sion-making on new vaccine
introduction
 Create concise and effective technical
presentations based on data from the
economic analysis performed
 Construct key messages and provide
supporting evidence to accompany
the results of the economic analyses
 Draft policy briefs that include the
national economic analysis and other
relevant criteria for decision-making
 Draft technical reports, including more
detailed information about the eco-
nomic evaluation that was conducted
The public, healthcare workers,
community leaders, the
media
 A culturally-appropriate approach
 Boost skills of healthcare teams in
community dialogue and other interac-
tive techniques
 Engage local and national media as
well as social media, if appropriate
 Provide training in crisis
communications
 Adapt strategy as appropriate,
responding to evolving communication
needs
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strategies must be appropriate for the population to be vaccinated
and developed on a local level. This was the aim of the Meningitis
Vaccine Project (MVP) communication strategy in Africa [85]. Early
in the project, a strategy was developed to engage the media, com-
munity leaders, populations to be targeted for vaccination
(younger than 30 years) and healthcare professionals. The strategy
was adapted as the project matured. For example, it became clear
that many local journalists needed better scientific understanding
of the project so regular media workshops and information
updates were included in the communications plan. To address
the challenge of convincing adolescents and young adults to take
part in the vaccination campaigns, MVP employed peer education,
targeted social mobilisation messages, participation of celebrities
known by young people and launched vaccination campaigns in
universities and schools. In other populations, community discus-
sions with the aim of engaging tribal and administrative leaders
improved outreach to desired targets. Training in crisis communi-
cations, including preparation of crisis management plans, was
also an important component of the MVP strategy. The communi-
cation strategy proved to be key to the successful introduction of
the meningococcal vaccine in Africa, due mainly to its early imple-
mentation, culturally-appropriate approach and emphasis on
boosting the skills of healthcare teams in community dialogue.
It is important that communication strategies evolve over time,
responding to any changes in vaccine coverage levels as well as
populations’ expectations and knowledge of immunisation services
[85,86].6. Conclusions
A well-functioning vaccination programme is a fundamental
ingredient of successful public health interventions against infec-
tious diseases. To optimise outcomes, an effective and efficient
immunisation service requires careful planning, execution and
monitoring. It is important to consider the viability of implementa-
tion strategies in terms of feasibility and cost of the proposed
immunisation schedule, likely adherence to and acceptance of vac-
cination by the target population, the healthcare structure in place
for vaccine delivery and compatibility with existing immunisation
calendars. The capacity to make evidence-based vaccine policy
decisions followed by the efficient introduction and management
of immunisation programmes is also evaluated. Lack of appropriate
infrastructure must be addressed in less developed countries, par-
ticularly for vaccines administered to age groups beyond early
childhood.
Experience and research have shown which vaccine strategies
work well and the factors that encourage success, which often
include strong support from government and healthcare organisa-
tions, and tailored, culturally-appropriate approaches. There is no
one-size-fits-all solution and vaccine strategies have to be adapted
according to local conditions.Contributorship
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